XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago.
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's preferred shares, XOMAP and XOMAO, offer high, reliable dividends, making them attractive for income investors seeking biotech exposure. XOMA's robust financials, including substantial cash reserves and non-dilutive financing, ensure the sustainability of dividend payments for many years.
XOMA Stock Dips Amidst Biotech Sector Decline
XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%.
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago.
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
